跳至主要内容
临床试验/NCT07694700
NCT07694700进行中(未招募)4 期

Comparative Study of Efficacy and Safety Between Combination of Colistin and Meropenem and Combination of Amikacin and Meropenem for Multi-Drug-Resistant Gram-Negative Bacteria.

Beni-Suef University1 个研究点 分布在 1 个国家目标入组 100 人开始时间: 2025年12月30日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
进行中(未招募)
入组人数
100
试验地点
1
主要终点
clinical cure at 72 hours

研究概览

简要总结

Objective of this study is to compare the efficacy and safety between combination of colistin and meropenem and combination of amikacin and meropenem for multi-drug-resistant gram-negative bacteria in Intensive Care Unit. In Beni- Suef University Hospital.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 70 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Study will include adult patient (male, female).
  • Patient age from 18 to 70 years.
  • Patient will be admitted to intensive care unit in study period (six months), who will receive intravenous colistin and meropenem or amikacin and meropenem as antimicrobial drug for treatment their MDR gram negative infection

排除标准

  • Patients are admitted to intensive care unit younger than 18 years or older than 70 years.
  • Patients are chronic kidney disease (CKD on hemodialysis or baseline creatinine clearance (crcl) < 10 ml/min (estimated by Cockcroft Gault equation).
  • Patients received renal replacement therapy before or during admission.
  • Patients are on any other nephrotoxic drug (vancomycin, NSAIDs, cyclosporine, amphotericin B, etc.)).
  • Pregnant and lactating women.
  • Patients refused the consent of the study.

研究组 & 干预措施

amikacin and meropenem

Active Comparator

50 patients received intravenous amikacin 15 to 30 mg/kg once daily and intravenous meropenem 2gm every 8hrs

干预措施: Amikacin Injection and meropenem (Drug)

colistin and meropenem

Active Comparator

50 patients received intravenous colistin 300 mg colistin base activity (CBA) as loading dose, followed by 2.5-5mg/kg/day of CBA in 2 divided doses as a maintenance dose and intravenous meropenem 2gm every 8hrs

干预措施: Colistimethate sodium for injection, meropenem (Drug)

结局指标

主要结局

clinical cure at 72 hours

时间窗: 72 hours

Number of participants achieving clinical cure, defined as resolution of fever and improvement of the baseline signs and symptoms of infection without the need to change or escalate antibiotic therapy.

Body temperature

时间窗: 72 hours

Body temperature measured at baseline and 72 hours after initiation of antibiotic therapy.

White blood cell count

时间窗: 72 hours

White blood cell (WBC) count measured at baseline and 72 hours after initiation of antibiotic therapy.

次要结局

  • Serum creatinine level(72 hours)
  • 14- day survival rate(14 days)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Asmaa Nafady Abdelfattah

pharmacist

Beni-Suef University

研究点 (1)

Loading locations...

相似试验